The Paroxysmal Nocturnal Hemoglobinuria (PNH) market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several key factors, including the rising prevalence of PNH, increasing awareness and diagnosis rates, and advancements in treatment options. The market is characterized by a growing...